scholarly journals Radiation Segmentectomy

2021 ◽  
Vol 38 (04) ◽  
pp. 425-431
Author(s):  
Kristina Prachanronarong ◽  
Edward Kim
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radiation Dose ◽  
Effective Treatment ◽  
Small Volume ◽  
Outcome Data ◽  
Therapeutic Modality ◽  
High Radiation ◽  
Transarterial Radioembolization ◽  
Surrounding Parenchyma ◽  
Yttrium 90

AbstractRadiation segmentectomy is an yttrium-90 transarterial radioembolization treatment where a high radiation dose is administered to a small volume of liver to achieve a high tumoricidal dose to a target with anatomic surgical precision while sparing surrounding parenchyma. This therapeutic modality is often used to treat hepatocellular carcinoma, and recent studies have demonstrated that radiation segmentectomy is an effective treatment as a neoadjuvant to transplant, resection, or as a standalone treatment. This article provides a review of radiation segmentectomy, indications for treatment, recent outcome data, and guidelines for postprocedural management.

scholarly journals Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma

2016 ◽  
Vol 33 (5) ◽  
pp. 699-714 ◽  
Author(s):  
Joseph Ralph Kallini ◽  
Ahmed Gabr ◽  
Riad Salem ◽  
Robert J. Lewandowski
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transarterial Radioembolization ◽  
Yttrium 90

scholarly journals Yttrium-90 Microspheres for Intermediate- or Advanced-Stage Hepatocellular Carcinoma

2021 ◽  
Vol 1 (3) ◽  
Author(s):  
Calvin Young ◽  
Anusree Subramonian ◽  
Charlene Argáez
Keyword(s):  
Hepatocellular Carcinoma ◽  
Adverse Events ◽  
Transarterial Chemoembolization ◽  
Systemic Treatment ◽  
Cost Effective ◽  
Economic Evaluations ◽  
Advanced Stage ◽  
Transarterial Radioembolization ◽  
90Y Microspheres ◽  
Yttrium 90

Transarterial radioembolization using yttrium-90 (90Y) microspheres is a therapeutic option for patients with intermediate- or advanced-stage hepatocellular carcinoma, including those with recurrent or inoperable hepatocellular carcinoma. Overall, the evidence suggests that patients treated with 90Y-based transarterial radioembolization may experience no difference in overall survival, progression-free survival, and tumour response when compared to patients who received transarterial chemoembolization therapies or systemic treatment with sorafenib or lenvatinib. Patients treated with transarterial radioembolization generally experienced similar rates of adverse events compared to those treated with transarterial chemoembolization, although there were some instances where treatment with transarterial radioembolization led to increased or decreased risks of specific adverse events. The comparative safety of transarterial radioembolization versus systemic treatment with sorafenib was unclear as the included studies did not statistically compare the risks of experiencing adverse events. Evidence regarding the cost-effectiveness of 90Y microspheres for treating hepatocellular carcinoma is conflicting. Three economic evaluations suggest treatment with transarterial radioembolization is likely to be cost-effective or dominant — less costly and more effective — compared to transarterial chemoembolization or systemic therapies, while a single economic study suggested treatment with sorafenib or lenvatinib is most likely to be cost-effective or dominant compared to transarterial radioembolization.

Therapy for inoperable hepatocellular carcinoma with selective transarterial radioembolization with yttrium-90 microspheres

2018 ◽  
Vol 7 (3) ◽  
pp. 55
Author(s):  
K. V. Lyadov ◽  
A. D. Kaprin ◽  
A. G. Rerberg ◽  
I. A. Kozyrin ◽  
V. K. Lyadov ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transarterial Radioembolization ◽  
Yttrium 90

Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib

2018 ◽  
Vol 14 (8) ◽  
pp. 727-735
Author(s):  
Maria Grazia Lucà ◽  
Roberto Nani ◽  
Melanie Schranz ◽  
Massimo De Giorgio ◽  
Claudia Iegri ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Cost Analysis ◽  
Transarterial Radioembolization ◽  
Yttrium 90

scholarly journals Survival Outcomes for Yttrium-90 Transarterial Radioembolization With and Without Sorafenib for Unresectable Hepatocellular Carcinoma Patients

2020 ◽  
Vol Volume 7 ◽  
pp. 117-131
Author(s):  
Ajalaya Teyateeti ◽  
Armeen Mahvash ◽  
James P Long ◽  
Mohamed E Abdelsalam ◽  
Rony Avritscher ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Survival Outcomes ◽  
Transarterial Radioembolization ◽  
Unresectable Hepatocellular Carcinoma ◽  
Yttrium 90

scholarly journals Labeling of Hinokitiol with 90Y for Potential Radionuclide Therapy of Hepatocellular Carcinoma

Processes ◽  
2021 ◽  
Vol 9 (6) ◽  
pp. 940
Author(s):  
Christelle Bouvry ◽  
Valérie Ardisson ◽  
Nicolas Noiret ◽  
Etienne Garin ◽  
Nicolas Lepareur
Keyword(s):  
Hepatocellular Carcinoma ◽  
Radionuclide Therapy ◽  
Liver Tumors ◽  
Potential Treatment ◽  
Primary Liver Tumors ◽  
Transarterial Radioembolization ◽  
The World ◽  
Yttrium 90

Hepatocellular carcinoma (HCC), the most common form of primary liver tumors, is the fifth cancer in the world in terms of incidence, and third in terms of mortality. Despite significant advances in the treatment of HCC, its prognosis remains bleak. Transarterial radioembolization with radiolabeled microspheres and Lipiodol has demonstrated significant effectiveness. Here we present a new, simple radiolabeling of Lipiodol with Yttrium-90, for the potential treatment of HCC.

Sign in / Sign up

Export Citation Format

Share Document